Company profile for OWP Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

OWP Pharmaceuticals enjoys a heartfelt, strategic and innovative relationship with the ROW Foundation. Together they form a concerted organization with shared goals and values that result in a true Pharmaceutical Social Enterprise. OWP uses commercial success for the common good by supporting humanitarian projects rather than maximizing profits. OWP Pharmaceuticals delivers quality branded generic neuroscience medications that...
OWP Pharmaceuticals enjoys a heartfelt, strategic and innovative relationship with the ROW Foundation. Together they form a concerted organization with shared goals and values that result in a true Pharmaceutical Social Enterprise. OWP uses commercial success for the common good by supporting humanitarian projects rather than maximizing profits. OWP Pharmaceuticals delivers quality branded generic neuroscience medications that are replicable and fairly priced.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Naperville, IL 60563
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/owp-pharmaceuticals-selects-eversana-to-support-us-launch-of-subvenite-lamotrigine-oral-suspension-302592536.html

PR NEWSWIRE
23 Oct 2025

http://www.pharmabiz.com/NewsDetails.aspx?aid=145069&sid=2

PHARMABIZ
06 Jan 2022

https://www.globenewswire.com/news-release/2021/11/17/2336301/0/en/OWP-Pharmaceuticals-Announces-IND-Authorization-for-the-First-Ever-Oral-Liquid-Formulation-of-Atomoxetine-Hydrochloride-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disorde.html

GLOBENEWSWIRE
17 Nov 2021

https://www.globenewswire.com/news-release/2021/07/01/2256446/0/en/OWP-Pharmaceuticals-Announces-Patent-Issuance-for-the-First-Ever-Oral-Liquid-Suspension-of-Quetiapine-for-the-Treatment-of-Schizophrenia-and-Bipolar-Disorder.html

GLOBENEWSWIRE
01 Jul 2021

https://www.globenewswire.com/news-release/2021/04/22/2215011/0/en/OWP-Pharmaceuticals-Announces-Patent-Application-for-the-First-Ever-Oral-Liquid-Formulation-of-Atomoxetine-Hydrochloride-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disord.html

GLOBENEWSWIRE
22 Apr 2021

https://www.biospace.com/article/releases/owp-pharmaceuticals-announces-ind-approval-for-the-first-ever-liquid-oral-suspension-formulation-of-quetiapine-fumarate-for-the-treatment-of-schizophrenia-and-bipolar-disorder/

BIOSPACE
07 Oct 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty